Health
Helio Genomics to Make HelioLiver™ Cancer Test Accessible to Quest Diagnostics' Providers
Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today announced an agreement with Quest Diagnostics, a leading provider of diagnostic information services, to make HelioLiver™, Helio Genomics' innovative blood-based early detection test for Hepatocellular Carcinoma (HCC), widely available to physicians and patients through Quest's extensive U.S. network. The test aims to help power earlier intervention in patients who are at risk of developing HCC, the most commo
About this update from Quest Diagnostics Incorporated
[{"type":"text","content":"Quest's Infrastructure to Enable Access to HelioLiver™, an AI-Powered, Blood-Based Test for Early Detection of Liver Cancer","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"IRVINE, Calif., March 18, 2026 /PRNewswire/ -- Helio Genomics, an AI-powered TechBio company focused on early cancer detection, today announced an agreement with Quest Diagnostics, a leading provider of diagnostic information services, to make HelioLiver™, Helio Genomics' innovative blood-based early detection test for Hepatocellular Carcinoma (HCC), widely available to physicians and patients through Quest's extensive U.S. network. The test aims to help power earlier intervention in patients who are at risk of developing HCC, the most common primary liver cancer. Starting in April, any healthcare provider with a Quest account will be able to order the test.","length":744,"tagName":"p"},{"type":"text","content":"HelioLiver™ is designed to fit into routine liver cancer surveillance with a simple blood draw. By integrating cell-free DNA methylation patterns, protein biomarkers, and patient demographics using a proprietary AI algorithm, HelioLiver™ aims to provide an additional source of risk and disease signal at an early stage, even when ultrasound findings may be limited or not yet definitive.","length":413,"tagName":"p"},{"type":"text","content":""This agreement with Quest Diagnostics is an important step in our mission to democratize early cancer detection," said Dr. Bharat Tewarie, CEO of Helio Genomics. "By harnessing Quest's vast scale and infrastructure, our goal is to expand access to tools that physicians can use to aid detection of liver cancer at its most treatable stage, ultimately driving better patient outcomes and redefining survivorship in oncology."","length":464,"tagName":"p"},{"type":"text","content":"The HelioLiver™ test addresses critical gaps in current methods, offering superior sensitivity to ultrasound for early-stage detection in high-risk individuals 1,2,3, such as those with cirrhosis or hepatitis B. (Current AASLD guidelines recommend that these patients undergo routine testing every six months) Under the agreement, Quest's provide...